

# Multi-effective characteristics and advantages of acupuncture in COVID-19 treatment

Lifen Wang<sup>1</sup>, Xiyou Hu<sup>1</sup>, Lianqi Geng<sup>2</sup>, Ningcen Li<sup>1</sup>, Yong Chen<sup>1</sup>, Jingyu Zhang<sup>1</sup>, Xinru Yuan<sup>1</sup>, Lihong Huang<sup>1</sup>, Dongsheng Ba<sup>1</sup>, Jinyu Lian<sup>1</sup>, Xiaoyan Lyu<sup>1</sup>, Zelin Chen<sup>1,3,4</sup>, Yue Zhang<sup>5,\*</sup>, Bo Chen<sup>2,3,\*</sup>

## Abstract

Coronavirus disease 2019 (COVID-19) is a major disease that threatens human life and health. Its pathogenesis is complex and still not fully clarified. The clinical treatment is mainly supportive and lacks specific treatment methods. Acupuncture treatment can inhibit immune inflammatory reactions, neuroinflammatory reactions, oxidative stress levels, and hypothalamus-pituitary-adrenal (HPA) axis activity, improve lung function, and relieve migraine, fatigue, anxiety, and depression. However, whether acupuncture treatment is suitable for treating these symptoms in patients with COVID-19 still needs to be investigated. For this review, the literature was systematically searched for multiple databases to summarize the mechanisms of acupuncture treatment for COVID-19-related symptoms and complications. A complex network analysis of acupoints and symptoms was also performed to clarify acupoint selection in the acupuncture treatment of symptoms related to COVID-19. The evidence indicates that acupuncture can improve the respiratory, digestive, nervous, and mental and psychological symptoms related to COVID-19 by inhibiting immune inflammatory reactions, regulating intestinal flora, mitochondrial function, oxidative stress level, cardiomyocyte apoptosis, neurotransmitter release, and HPA axis activity, and alleviating basic diseases such as diseases of the vascular system. Acupuncture can improve various clinical and concomitant symptoms of COVID-19; however, its mechanism of action is complex and requires further study.

**Keywords:** Acupuncture, COVID-19, Inflammatory factor storm, Multi-efficiency

**Graphical abstract:** <http://links.lww.com/AHM/A54>.

## Introduction

Coronavirus disease 2019 (COVID-19) is an acute infectious pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a highly contagious and universal susceptibility in the population.

Most infected individuals have mild symptoms and recover well, whereas those with severe disease develop severe pneumonia, pulmonary edema, acute respiratory distress syndrome (ARDS), or multiple organ failure and death<sup>[1]</sup>. According to official data from the World Health Organization, as of December 18, 2022, the cumulative number of confirmed COVID-19 cases worldwide exceeded 649 million, with more than 6.6 million deaths and a mortality rate of 1.02%. Therefore, the COVID-19 pandemic has become a public health emergency of international concern<sup>[2]</sup>. In many cases, patients with COVID-19 do not die of the infection, but from the inflammatory disease that follows the infection. An “inflammatory factor storm,” also known as “cytokine storm syndrome,” is an important factor in the rapid deterioration and even death of patients with COVID-19<sup>[3]</sup>. Following the invasion of the body, the virus causes a loss of the negative feedback of immune regulation and abnormal elevation of multiple cytokines, which activate and recruit more immune cells, causing diffuse damage to pulmonary capillary endothelial cells and alveolar epithelial cells and massive exudate obstruction of the airway, finally resulting in ARDS. Subsequently, cytokines enter the bloodstream and circulate throughout the body, causing further single-organ or multiple organ damage and failure<sup>[4]</sup>. As the pandemic progresses, several countries around the world have issued treatment guidelines or guidance for COVID-19. *The COVID-19 Treatment Guidelines* issued by the National Institutes of Health on January 26, 2023<sup>[5]</sup>, and *the COVID-19 Diagnosis and Treatment Plan (Trial Version 10)* issued by the Health Commission of China<sup>[6]</sup> are consistent in terms of overall treatment principles and improving

Lifen Wang and Xiyou Hu contributed equally to this work.

<sup>1</sup> Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China; <sup>2</sup> School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, China; <sup>3</sup> Fourth Teaching Hospital of Tianjin University of TCM Binhai New Area Hospital of TCM Tianjin, Tianjin, China; <sup>4</sup> National Clinical Research Center of Traditional Chinese Medicine and Acupuncture, Tianjin, China; <sup>5</sup> Department of Neurosurgery, University of Pennsylvania, Philadelphia, the United States of America

\*Corresponding author: Bo Chen, School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; Fourth Teaching Hospital of Tianjin University of TCM Binhai New Area Hospital of TCM Tianjin, Tianjin 300451, China, E-mail: [tjutcmchenbo@163.com](mailto:tjutcmchenbo@163.com); Yue Zhang, Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA 19104, USA, E-mail: [yue.zhang@penntcm.upenn.edu](mailto:yue.zhang@penntcm.upenn.edu)

Copyright © 2023 Tianjin University of Traditional Chinese Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Acupuncture and Herbal Medicine (2023) 3:2

Received 9 September 2022 / Accepted 6 March 2023

<http://dx.doi.org/10.1097/HM9.000000000000062>

patients' symptoms through antiviral, immunosuppressive, and hormonal therapy, as well as corresponding organ supportive therapy. Currently, clinical treatment mostly involves symptomatic supportive treatment, as long-term medication could aggravate immunosuppressive conditions, toxic side effects on the heart, and the burden on the liver and kidneys in the later stages of the disease<sup>[3,7]</sup>. There is no suitable Western medicine for injuries to multiple organs caused by cytokine storm, nor for anxiety, depression, insomnia, and other symptoms after the disease. Re-administration of medication may cause secondary injury to patients owing to side effects<sup>[8-9]</sup>. Therefore, it is necessary to seek new treatment strategies, especially for high-risk groups such as older patients with cardiovascular and other basic diseases.

Since the outbreak of the COVID-19 pandemic, long COVID has become widespread globally. According to World Health Organization statistics, the incidence rate of long COVID is 10%–20%<sup>[10]</sup>. The pathogenesis of long COVID is extremely complex, including inflammatory reactions<sup>[11]</sup>, immune disorders<sup>[12]</sup>, intestinal flora disorders<sup>[13]</sup>, endothelial dysfunction<sup>[14]</sup>, and other pathophysiological processes caused by SARS-CoV-2. In addition to the respiratory system, the digestive, nervous, and mental systems of patients with long COVID are affected to varying degrees, with cough, dyspnea, headache, diarrhea, anxiety, depression, fatigue, and other sequelae<sup>[15]</sup>. However, extensive and effective treatment methods for long COVID are lacking. Leukotriene receptor antagonists, antiviral drugs, non-steroidal anti-inflammatory drugs, antihistamine famotidine, low-dose naltrexone, coenzyme Q10, and antidepressants are often used in the treatment of long COVID; however, the efficacy of these treatments is uncertain, and long-term use of these drugs will increase the burden on the liver and kidneys, cause gastrointestinal reactions, and aggravate diarrhea, nausea, vomiting, and other symptoms<sup>[16-17]</sup>.

As a non-drug therapy, acupuncture regulates the body's surface have essential characteristics and advantages for preventing and treating long COVID. A systematic review and meta-analysis of 12 randomized controlled trials (RCTs) involving 597 people with advanced dyspnea [347 chronic obstructive pulmonary diseases (COPD), 190 advanced cancer] showed that acupuncture improved dyspnea and quality of life in people with advanced disease<sup>[18]</sup>. A multi-center RCT involving 150 patients with migraine showed that acupuncture safely reduced the severity of migraine<sup>[19]</sup>. Other studies found that acupuncture treatment can inhibit immune inflammatory reactions, neuroinflammatory reactions, oxidative stress levels, and hypothalamus-pituitary-adrenal (HPA) axis activity; improve lung function, and relieve migraine, fatigue, anxiety, and depression<sup>[20-23]</sup>. However, whether acupuncture treatment is suitable for the treatment of these symptoms in patients with COVID-19 still needs to be investigated. Therefore, we reviewed the literature to summarize the mechanisms of acupuncture treatment for COVID-19-related symptoms.

We systematically searched for articles published up to July 2022 in PubMed, Web of Science, and Embase, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang Database. The search terms were ("acupuncture" OR "electroacupuncture" OR "auricular points" OR "fire needling" OR "transchannel electrical nerve stimulation" OR "TENS" OR "acupoint injection") AND ("novel coronavirus pneumonia" OR "COVID-19" OR "2019-nCoV" OR "coronavirus release 2019"). Seventeen clinical studies and case reports of acupuncture treatment for COVID-19 were included. See Supplementary Digital Content 1, <http://links.lww.com/AHM/A52>, for the detailed retrieval strategy. Using Cytoscape 3.6.0 software for the visual display, a complex network analysis was performed of acupuncture points and symptoms related to the respiratory, digestive, nervous, and cardiovascular systems and psycho-psychological disorders of patients with COVID-19. The rules of acupoint selection in the acupuncture treatment of symptoms related to COVID-19 were summarized, and the mechanism of acupuncture treatment was explored. The findings of this review are expected to serve as a reference for clinical decision-making and the application of acupuncture in the prevention and treatment of COVID-19-related symptoms and long COVID sequelae.

## Therapeutic role of acupuncture in COVID-19-related symptoms

### *Acupuncture treatment for COVID-19-related symptoms related to the respiratory, digestive, and nervous systems*

COVID-19 is an infectious disease caused by SARS-CoV-2, with the lung as the main target organ. In addition to the typical clinical manifestations of respiratory infections such as fever, cough, expectoration, pharyngalgia, chest tightness, and dyspnea. COVID-19 causes other atypical symptoms such as diarrhea, nausea and vomiting, anorexia, headache, dizziness, and fatigue<sup>[24]</sup>.

### *Acupuncture for respiratory symptoms related to COVID-19*

SARS-CoV-2 mainly infects alveolar epithelial cells and induces a high local inflammatory state. Persistent inflammation can lead to lung tissue injury and a series of respiratory symptoms<sup>[25]</sup>. Ten systematic reviews/meta-analyses including 134,222 patients demonstrated that the most common symptoms experienced by patients with COVID-19 were fever (78.0%–91.3%)<sup>[26-35]</sup>, cough (52.0%–72.2%)<sup>[26-35]</sup>, dyspnea (10.4%–45.6%)<sup>[29-30,32,34-35]</sup>, expectoration (21.3%–41.8%)<sup>[26,30,34]</sup>, chest distress (31.2%), and sore throat (13.1%)<sup>[26,32]</sup>. Clinical guidelines such as the *American Clinical Practice Guidelines* recommend acupuncture for the clinical treatment of allergic rhinitis and acute pharyngitis<sup>[36-37]</sup>. A randomized clinical study including 32 patients with asthma showed that acupuncture treatment could increase forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and FEV1/FVC and improve the respiratory function of the patients<sup>[38]</sup>. Several systematic evaluations have shown that acupuncture can relieve symptoms

such as cough, expectoration, and dyspnea in patients with COPD and cough variant asthma and improve lung function<sup>[39–40]</sup>.

Several studies have demonstrated that acupuncture can improve respiratory function by regulating the balance of helper T cells, promoting macrophage polarization, and modulating inflammatory signaling pathways and cytokines. Imbalances in between helper T cells (Th1/Th2) and regulatory T cells (Treg/Th17) play a key role in the inflammatory immune response of respiratory diseases<sup>[41–44]</sup>, and acupuncture can increase the levels of IFN- $\gamma$  in bronchoalveolar lavage fluid (BALF), reduce the levels of interleukin (IL)-4, IL-17, and transforming growth factor beta (TGF- $\beta$ ), regulate the balance of CD4<sup>+</sup> T lymphocyte subsets (Th1/Th2 and Treg/Th17), and improve airway inflammation<sup>[45]</sup>. Acupoint catgut embedding promotes macrophage polarization, reduces BALF tumor necrosis factor (TNF)- $\alpha$  and IL-6 levels, upregulates IL-10 levels, reduces local inflammatory responses, and improves respiratory function<sup>[46]</sup>. Additionally, EA downregulates the JAK/STAT pathway to inhibit IL-6 and TNF- $\alpha$ , thereby improving COPD<sup>[47–48]</sup>. A study has shown that EA can reduce the levels of TNF- $\alpha$  and IL-1 $\beta$  in BALF in rats with COPD, as well as improve pathological lung damage<sup>[49]</sup>.

#### Acupuncture for digestive symptoms related to COVID-19

With continuous research on COVID-19, digestive system symptoms were found to occur during the course of treatment. Some patients report digestive system symptoms as the first symptoms of COVID-19, and they are more likely to develop severe COVID-19<sup>[50]</sup>. Four systematic reviews/meta-analyses including 19,007 patients showed that the pooled prevalence of digestive symptoms was 9.8%–17.6%<sup>[51–53]</sup>, with diarrhea (7.8%–12.9%)<sup>[26,51–52,54]</sup>, nausea or vomiting (5.5%–10.2%)<sup>[26,51–52,54]</sup>, abdominal discomfort/pain (3.0%–6.9%)<sup>[51–52]</sup>, and loss of appetite (11%)<sup>[52]</sup> being the most common symptoms. Although acupuncture for COVID-19 digestive symptoms has not been evaluated in a clinical trial, there is abundant evidence of its effect on digestive symptoms. The American Society of Clinical Oncology (ASCO) recommends acupoint pressing and acupuncture to alleviate nausea and vomiting after chemotherapy. ASCO also suggests that EA can be used as a supplement to antiemetic drugs during chemotherapy (level B)<sup>[55]</sup>. Several clinical trials have shown that acupuncture can improve the symptoms of diarrhea, abdominal distension, nausea and vomiting, and improve the quality of life of these patients<sup>[56–57]</sup>. Several systematic evaluations and meta-analyses have shown that acupuncture can improve nausea, vomiting, anorexia, and other symptoms without adverse events<sup>[58–59]</sup>.

An imbalance in the intestinal microbiota changes the intestinal mucus layer, destroys the tight connections, increases intestinal permeability, and promotes bacterial translocation<sup>[60]</sup>. Destruction of the intestinal barrier leads to the transfer of intestinal bacteria or harmful antigens to the host's immune system and promotes the development of intestinal inflammation<sup>[61]</sup>. Acupuncture can reduce intestinal bacterial translocation, protect the intestinal mucosal barrier, regulate visceral

hypersensitivity, and improve gastrointestinal function by inhibiting inflammatory reactions and mast cell activity and reducing intestinal permeability. Research has shown that EA can increase the numbers of *Lactobacillus* sp. and *Trichospiraceae* in the intestine, reduce the numbers of *Clostridium bifurcans*, and improve the diversity and number of beneficial flora to correct intestinal flora disorders<sup>[62]</sup>. EA can reduce colon tissue TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and inducible nitric oxide synthase levels; increase IL-10 levels; upregulate the expression of ZO-1, occludin, E-cadherin, and mucin 2 (MUC2) in the colon tissue; inhibit intestinal epithelial cell apoptosis; and reduce intestinal permeability<sup>[63]</sup>. Visceral hypersensitivity is the main pathogenesis of functional dyspepsia<sup>[64]</sup>, and mast cell activation is closely related to visceral hypersensitivity. EA can inhibit the activity of degranulated mast cells in colon tissue and reduce serum IL-1 and IL-8 concentrations to regulate visceral hypersensitivity<sup>[65]</sup>.

#### Acupuncture nervous system symptoms related to COVID-19

Autopsy, animal, and organoid studies have shown that SARS-CoV-2 can reach and infect central nervous system cells and neurons and produce neuroinflammation<sup>[66]</sup>. According to statistics, 36% of patients with COVID-19 have nervous system symptoms<sup>[67]</sup>, with headache (12.1%–42%), dizziness (12.1%), and fatigue (35.5%–51.0%)<sup>[30,32,35]</sup> being the most common symptoms. The results of a cohort study showed that acupuncture could effectively improve dizziness, vertigo, and other symptoms<sup>[68]</sup>. In 2017, the American Cancer Society published a guide on complications during treatment for breast cancer, recommending acupuncture to improve fatigue after cancer treatment (level C)<sup>[69]</sup>. Subsequently, a systematic review and meta-analysis including 31 RCTs with 2,255 patients for chronic fatigue syndrome (CFS) showed that acupuncture was better than traditional Chinese medicine, Western medicine, or sham acupuncture in alleviating fatigue<sup>[70]</sup>. A randomized clinical trial including 150 patients with migraine without aura showed that acupuncture could significantly improve the number of attacks and pain intensity in patients with migraine<sup>[19]</sup>. A recent meta-analysis of 13 RCTs with 1,559 patients with migraine found that EA is more effective for reducing the severity of headaches than sham acupuncture<sup>[71]</sup>.

The analgesic and anti-fatigue effects of acupuncture are closely related to the downregulation of neurotransmitters and neuropeptides, such as glutamate, substance P (SP), and calcitonin gene-related peptide (CGRP), as well as anti-oxidative stress. Glutamic acid is the most common excitatory neurotransmitter in the central nervous system<sup>[72]</sup>. In addition, EA can inhibit the expression of glutamic acid in the hippocampus to reduce neuropathic pain in the higher regions of the brain<sup>[73]</sup>. EA can reduce the concentration of serum CGRP, reduce the mRNA expression of SP and CGRP in the dorsal cervical root ganglion, inhibit hyperalgesia, and relieve migraine<sup>[74]</sup>. Oxidative stress and lipid peroxidation are important factors in the occurrence of pain and fatigue<sup>[75]</sup>. A study on the analgesic effect of EA on paclitaxel-induced neuropathic pain showed


that under oxidative stress, EA upregulated the expression of Nrf2 antioxidant response element (Nrf2-ARE) and superoxide dismutase (SOD) in the dorsal cervical root ganglion enhanced the antioxidant signal pathway, and inhibited the oxidative stress products NOX4 and 8-iso-prostaglandin F<sub>2</sub>α (8-iso PGF<sub>2</sub> α) to reduce neuropathic pain<sup>[22]</sup>. In addition, a study showed that acupuncture intervention can affect the level of malondialdehyde and the activities of SOD and glutathione peroxidase, improve the antioxidant capacity of CFS rats, and alleviate fatigue<sup>[76]</sup>.

### Acupuncture for the treatment of mental and psychological disorders secondary to COVID-19

After the outbreak of the COVID-19 pandemic, the atmosphere of fear led to depression, anxiety, and sleep disorders among hospitalized patients, isolated people, and front-line medical staff<sup>[77]</sup>. A web-based survey of 4,283 participants from 101 countries found that the rates of depression and of anxiety, as well as insomnia caused by COVID-19 were 32.8% and 30.8%, respectively, and that the psychological effects were long-term<sup>[78]</sup>. A recent cohort study published in *The Lancet* showed that patients with COVID-19 mainly experienced sleep difficulties, anxiety, or depression 6

months after discharge<sup>[9]</sup>. The clinical practice guidelines for non-drug treatment and drug treatment of adult patients with major depression developed by the American College of Physicians in 2016 suggested that acupuncture treatment for major depression has fewer adverse reactions than drug treatment. Moreover, acupuncture combined with second-generation antidepressants is better than using second-generation antidepressants or acupuncture alone<sup>[79]</sup>. In 2018, ASCO proposed that acupuncture can be used to improve emotional disorders, anxiety, and depression in patients with breast cancer (level C)<sup>[55]</sup>. In 2022, a randomized clinical trial including 247 patients with depression and insomnia showed that EA could significantly improve anxiety, depression, and sleep quality<sup>[80]</sup>. Several meta-analyses have shown that acupuncture can effectively relieve anxiety and depression in patients and that it is very safe<sup>[81–82]</sup>.

Acupuncture can play a role in relieving anxiety and depression and promoting sleep by regulating neurotransmitters, immune inflammatory reactions, and HPA axis activity. Neurotransmitter and immune inflammatory reaction disorders are increasingly considered key factors in depression<sup>[83–84]</sup>. A study found that acupuncture has an antidepressant effect by upregulating the levels of neurotransmitters such as 5-hydroxytryptamine




**Figure 1.** Network topology of acupoints and respiratory symptoms. Circles represent common respiratory symptoms, and arrowheads present acupoints. Green represents the largest value, and blue is the smallest value. The larger the shape, the greater the value, and the closer the connection between the two nodes.

(5-HT), dopamine (DA), and norepinephrine (NE) in the hippocampus<sup>[85]</sup>. Acupuncture inhibits the expression of inflammatory factors such as IL-1 $\beta$ , IL-18, high mobility group box 1 (HMGB1), IFN- $\gamma$ , IL-6, and TNF- $\alpha$  in serum and the hippocampus and improves depressive-like behavior<sup>[86]</sup>. In addition, the HPA axis is closely related to anxiety, depression, and insomnia. EA can reduce the concentration of corticotropin-releasing hormones (CRH) in the hypothalamus and pituitary, as well as the concentrations of CRH, adrenocorticotropic hormone (ACTH), and cortisol (CORT) in the serum, indicating that acupuncture can relieve anxiety, depression, and sleep difficulties by inhibiting the activity of the HPA axis<sup>[23,87]</sup>.

**Acupuncture for the treatment of COVID-19 combined with cardiovascular and other underlying diseases**

Among patients with COVID-19, those with cardiovascular and other basic diseases are more likely to develop severe pneumonia, ARDS, or multiple organ failure owing to their decreased immunity, weak defense system, and reduced ability to withstand systemic cytokine storms, which will lead to an increase in the incidence

rate and mortality<sup>[1,88]</sup>. A study shown that 46.4% of 138 inpatients with COVID-19 had one or more basic diseases. The most common were hypertension (31.2%), cardiovascular disease (14.5%), and diabetes (10.1%)<sup>[50]</sup>. Another epidemiological survey of 257 patients with severe COVID-19 from a tertiary hospital showed that 82% had at least one chronic disease, of which the most common were hypertension (63%) and diabetes (36%)<sup>[89]</sup>. A systematic review and meta-analysis including 13 RTCs with 797 patients showed that the clinical efficacy of acupuncture for the treatment of paroxysmal supraventricular tachycardia (PSVT) was not lower than that of oral antiarrhythmic drugs<sup>[90]</sup>. A systematic review including 22 RCTs with 1,744 patients with primary hypertension showed that acupuncture had better immediate hypotensive effects than drug treatment<sup>[91]</sup>. A multiple centers large sample RCT report included 404 patients with chronic stable angina pectoris. The results showed that acupuncture as an auxiliary intervention method has a better effect in alleviating the frequency of angina attacks<sup>[92]</sup>. In addition, in 2019, a systematic review of 12 RCTs involving 974 patients with stable angina pectoris showed that acupuncture plus medication or acupuncture alone was more effective than medication alone in relieving angina pectoris and improving



**Figure 2.** Network topology of acupoints and digestive symptoms. Circles represent common digestive symptoms, and arrowheads represent acupoints. Green represents the largest value, and yellow is the smallest value. The larger the shape, the greater the value, and the closer the connection between the two nodes.


electrocardiogram ischemia markers<sup>[90,93]</sup>. In April 2021, the Chinese Medical Association officially released the *Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)*, in which “acupuncture combined with basic treatment to control blood glucose synergism” was included in the treatment recommendation<sup>[94]</sup>.

The mechanism of acupuncture in treating cardiovascular diseases is complex. Acupuncture can reduce cardiomyocyte apoptosis and improve cardiac function by inhibiting inflammatory reactions and improving mitochondrial functions. The mechanism of acupuncture in treating arrhythmia and hypertension is related to the renin-angiotensin-aldosterone system (RAAS). Studies have found that EA pretreatment can reduce myocardial caspase-1 and IL-1 $\beta$ , inhibit the activation of NLRP3 inflammatory bodies, and play a protective role in the heart<sup>[95]</sup>. EA pretreatment can promote the synthesis of adenosine triphosphate (ATP), inhibit the expression of ROS, upregulate the level of anti-apoptotic protein Bcl-2, improve mitochondrial dysfunction, reduce cardiomyocyte apoptosis, and improve myocardial injury<sup>[96]</sup>. EA can also significantly inhibit the degree of ST-segment elevation, improve left ventricular dysfunction, and reduce systolic and diastolic blood pressure by reducing the release of cardiac norepinephrine<sup>[97]</sup>. RAAS plays a role in causing vasoconstriction and raising blood pressure<sup>[98]</sup>. EA can reduce the


concentrations of angiotensin II (AngII) and endothelin-1 (ET-1) in plasma and the levels of angiotensin II type 1 receptor (AT1R) and endothelin-1 type A receptor (ETAR) in the aorta and myocardium and reduce blood pressure<sup>[99]</sup>. Hyperglycemia is related to insulin resistance and endothelial dysfunction. EA upregulates the expression of insulin receptor substrate 1 (IRS-1), PI3K, Akt2, and eNOS in vascular endothelium by activating the PI3K/Akt signal pathway, improves insulin sensitivity, improves endothelial dysfunction, and reduces blood glucose<sup>[100]</sup>.

### Complex network analysis of acupuncture treatment for COVID-19-related symptoms

Based on extracting the application characteristics of acupoints, complex network analysis was used for the acupoint-symptom analysis. Acupoint-symptom analysis reflects the close relationship between acupoints and symptoms through a complex network of acupoints and symptoms. The results showed that the most frequent respiratory symptoms related to COVID-19 were fever, cough, chest tightness, chest pain, dyspnea, and other symptoms, and the most frequently selected acupoints were Hegu (LI4), Dazhui (GV14), Neiguan (PC6), Quchi (LI11), and Dingchuan (EX-B1). The network topology of symptoms and acupoints related to the respiratory system is shown in Figure 1. The most frequent digestive



**Figure 3.** Network topology of acupoints and nervous system symptoms. Circles represent common nervous system symptoms, and arrowheads represent acupoints. Green represents the largest value, and blue is the smallest value. The larger the shape, the greater the value, and the closer the connection between the two nodes.



**Figure 4.** Network topology of acupoints and symptoms of mental disorders. Circles represent common symptoms of mental disorders, and arrowheads represent acupoints. Blue represents the largest value, and yellow is the smallest value. The larger the shape, the greater the value, and the closer the connection between the two nodes.

symptoms related to COVID-19 were constipation, anorexia, diarrhea, abdominal distension, nausea, vomiting, abdominal pain, and other symptoms, and the most frequently used acupoints were Zusanli (ST36), LI4, Qihai (CV6), Guanyuan (CV4), and Sanyinjiao (SP6). The network topology of symptoms and acupoints related to the digestive system is shown in Figure 2. The most frequent neurological symptoms related to COVID-19 were fatigue, headache, olfactory dysfunction, limb pain, and dizziness, and the most frequently used acupoints were ST36, SP6, LI4, LI11, and Mingmen (GV4). The network topology of symptoms and acupoints related to the nervous system is shown in Figure 3. The most frequent symptoms of mental and psychological disorders related to COVID-19 were insomnia, anxiety, depression, and other symptoms, and the most frequently used acupoints were Shenmen (HT7), PC6, ST36, Baihui (GV20), and Ear trigical. The network topology of symptoms and acupoints related to mental and psychological disorders is shown in Figure 4.

Methods of acupuncture for the treatment of COVID-19-related symptoms were mainly manual acupuncture, followed by filiform-fire needling, tube needle, thumb-tack needles, ear point pressure, intradermal needle, and acupoint injection. Manual acupuncture, filiform-fire needling, and acupoint injection were performed once

daily or every other day and the needle was kept in place for 20–30 min. Thumb-tack needle and auriculopressure interventions lasted for 7h, 12h, or up to 1 day before discharge. However, owing to the varying severity of COVID-19-related symptoms and individual physical differences between patients, there is no uniform standard for the treatment period. In the analyzed literature, the shortest treatment period was 2 days, and the longest was 4 months; alternatively, acupuncture treatment was administered immediately after admission until the patient was discharged. The therapeutic role of acupuncture in COVID-19-related symptoms was shown in Table 1.

### Summary and prospect

Acupuncture treatment of COVID-19-related symptoms involves multiple systems and levels. Acupuncture can improve COVID-19-related symptoms by inhibiting immune inflammatory reactions and regulating intestinal flora, mitochondrial function, oxidative stress levels, myocardial cell apoptosis, neurotransmitter release, and HPA axis activity. Acupuncture promotes the transformation of macrophages from M1 pro-inflammatory type to M2 anti-inflammatory type, regulates the balance of CD4<sup>+</sup> T lymphocyte subsets, and downregulates

**Table 1.****The therapeutic role of acupuncture in related symptoms of COVID-19**

| Author and publication time          | COVID-19 presentation/ stage | Intervention methods                  | Acupoints   | Acupuncture parameters  | Related symptoms  |
|--------------------------------------|------------------------------|---------------------------------------|---|---|---|
| Bhat et al., 2022 <sup>[101]</sup>   | Recovery period              | MA                                    | GV20, LI20, EX-B1, H7, LI11, GB8, GB21, GV25  | Four months   | Olfactory dysfunction, nasal congestion, runny nose, nausea, anxiety, depression, dizziness, insomnia   |
| Yin et al., 2021 <sup>[102]</sup>    | Severe disease               | MA                                    | LI11, LI4, ST40, PC6, KI3, EX-B1, SP6   | Fifteen days, once a day  | Fever, expectoration, chest tightness, dyspnea, cough, fatigue, anorexia  |
| Yin et al., 2021 <sup>[103]</sup>    | Severe disease               | MA                                    | KI3, SP6, EX-B1   | Once a day, everyday, 15–30 min for 9 days  | Chest tightness, dyspnea, anorexia, fatigue   |
| Tao et al., 2020 <sup>[104]</sup>    | Ordinary type                | MA                                    | KI3, SP6, EX-B1   | Once a day, everyday, 10 days, no needle left   | Dyspnea, fatigue, cough   |
| Luo et al., 2022 <sup>[105]</sup>    | Recovery period              | Filliform-fire needling               | GV4, GV12, BL43, ST36, ST37, ST39, ST40, LU11, LI1  | Every other day, 3 times a week, 3 times per course, 2 courses  | Fatigue, cough, chest tightness, shortness of breath, chills, anorexia, constipation, expectoration, limb soreness, sore throat   |
| Li et al., 2021 <sup>[106]</sup>     | Ordinary type                | Acupoint injection                    | GV20, GV14, GV9, GV4, GV3, BL24, BL17   | Once a day, everyday for 20 days  | Fever, sore throat, chest tightness, cough, insomnia, diarrhea, fatigue   |
| Wang et al., 2021 <sup>[107]</sup>   | Severe disease               | Intradermal needle                    | LU6, GV14, BL13   | 7 days/time, twice  | Dyspnea   |
| Cheng, 2021 <sup>[108]</sup>         | Severe disease               | MA                                    | LU1, LU6, ST36, LU11, GV14, EX-B1   | Once a day, everyday, 30 min, 2 days  | Dyspnea, olfactory dysfunction, cough, fatigue, headache, chest pain  |
| Wang et al., 2022 <sup>[109]</sup>   | Ordinary type                | MA                                    | GV14, GB20, BL12, BL13, BL17, BL20, LI10, SP4, ST25, CV4, TE6, LU6, LI4, CV6, CV12, ST36, LR3                                 | Alternate use of two groups of acupoints, Once a day, 20 min 5 times/ week  | Cough, sore throat, nasal congestion, fever, shortness of breath, insomnia, anorexia, headache, limb soreness, constipation, nausea, fatigue, chest tightness, diarrhea |
| Jania, 2021 <sup>[110]</sup>         | Long COVID                   | MA                                    | SP6, ST36, ST40, ST44, ST25, TE5, LU7, CV6, CV12, CV15, LR3, GB41, GV20, GV21, GV22, GV29, BL25, BL23, BL20, BL21, BL17, BL13 | Once a day, everyday, 25 min, 6 weeks   | Diarrhea, abdominal pain, abdominal distention, constipation, migraine, fever, chest tightness, hiccup, insomnia, dizzy   |
| Gong et al., 2021 <sup>[111]</sup>   | Ordinary type                | MA                                    | LU7, LI4, PC6, LI11, ST36, LR3, KI6, BL62   | Every other day for 30 min. Acupuncture treatment administered immediately after admission until the patient was discharged | Migraine, shortness of breath, constipation, insomnia, fever, cough, chest tightness, chest pain, stomach ache, anorexia, fatigue, insomnia, anxiety                    |
| Shi et al., 2021 <sup>[112]</sup>    | Ordinary type                | MA                                    | LI4, PC6, LI11, LU7, ST36, LR3, BL62, KI6, SP6  | Every other day, 30 min, 12 days or until the patient is discharged   | Chest tightness, chest pain, fatigue, anxiety, anorexia, insomnia   |
| Luo et al., 2022 <sup>[113]</sup>    | Recovery period              | MA                                    | CV4, ST36, LU9  | Once a day, 7 days per course, 2 courses  | Fever, cough, fatigue, expectoration, chest tightness, shortness of breath, anorexia, chilliness, constipation, limb soreness, dizziness, headache                      |
| Luo et al., 2021 <sup>[114]</sup>    | Mild disease                 | Ear point pressing                    | HT7, subcortical, lung, spleen, endocrine   | Five times per day, 2 min, continue until 1 day before discharge  | Insomnia, anxiety, depression   |
| Yang et al., 2021 <sup>[115]</sup>   | Ordinary type                | Auricular point sticking and pressing | HT7, subcortical, heart, pillow, middle ear, mouth, trifocal  | Three times per day, 30 s, 12 days  | Insomnia, anxiety, depression   |
| Gong et al., 2020 <sup>[116]</sup>   | Severe disease               | MA                                    | ST36, SP6, LR3, LI4, LU7, PC6, LI11   | Once a day, Everyday, 30min, 12 days or until the patient is discharged   | Fever, cough, chest pain, shortness of breath, anorexia, constipation, fatigue, insomnia, anxiety   |
| Robert et al., 2022 <sup>[117]</sup> | Long COVID                   | MA                                    | GV20, ST36, SP6, LR3, PC6, LI4, TE5, LI11   | Everyday, 30min, 7 days   | Fever, fatigue, olfactory dysfunction, anxiety, dyspnea, chest tightness, cough   |

Abbreviations: COVID-19, Corona Virus Disease 2019; MA, Manual acupuncture; EA, Electroacupuncture; GV20, Baihui; LI20, Yingxiang; GV25, Suliao; KI3, Taixi; EX-B1, Dingchuan; GV4, Mingmen; GV12, Shenzhu; GV3, Yaoyangguan; GV14, Dazhui; CV15, Jiawei; GV21, Qinding; GV22, Xinhui; ST36, Zusanli; ST37, Shangjuxu; ST39, Xiajuxu; ST40, Fenglong; BL43, Gaohuang; LU11, Shaoshang; LI1, Shangyang; GV9, Zhiyang; BL24, Qihai; BL17, Geshu; BL13, Feishu; BL20, Pishu; LU6, Kongzui; LU2, Yunmen; GB20, Fengchi; BL12, Fengmen; LI10, Shousanli; SP4, Gongsun; ST25, Tianshu; CV4, Guanyuan; TE6, Zhigou; CV6, Qihai; CV12, Zhongwan; LR3, Taichong; LI10, Shousanli; LU7, Lieque; LI4, Hegu; PC6, Neiguan; LI11, Quchi; GV29, Yingtang; SP6, Sanyinjiao; HT7, Shenmen; CV17, Danzhong; BL62, Shenmai; KI6, Zhaohai; LU9, Taiyuan; LI; GB8, Shuaigu; GB21, Jianjing; GB41, Zulinqi; ST44, Neiting; TE5, Waiguan; BL25, Dachangshu; BL23, Shenshu; BL21, Weishu.




the JAK/STAT and PI3K/Akt pathways to improve airway and lung inflammatory responses and respiratory functions. Acupuncture inhibits intestinal inflammatory reactions and mast cell activity and decreases intestinal permeability to reduce intestinal bacterial translocation, protect the intestinal mucosal barrier, regulate visceral hypersensitivity, and improve gastrointestinal functions. Acupuncture can inhibit the release of neurotransmitters and neuropeptides, reduce oxidative stress, and exert analgesic and anti-fatigue effects. Moreover, acupuncture regulates neurotransmitter release, immune inflammatory reactions, and HPA axis activity to improve anxiety, depression, and insomnia. Acupuncture inhibits inflammatory reactions, regulates mitochondrial function and RAAS, and reduces cardiomyocyte apoptosis to improve cardiac function and hypertension. The therapeutic role and possible mechanism of acupuncture in the treatment of COVID-19-related symptoms are shown in Figure 5.

The complex network analysis demonstrated that among the most frequently selected acupoints for respiratory system-related symptoms, LI4, GV14, and LI11 were used to relieve heat and asthma, PC6 was used to regulate *qi* and relieve pain, and EX-B1 was used to relieve asthma and cough. The most frequently selected acupoints for digestive system-related symptoms were ST36 and SP6 to strengthen the spleen and stomach, LI4 to relieve static pain, LI11 to regulate *qi* to relieve

pain, and CV4 and CV6 to strengthen the intestine and stop diarrhea. For nervous system-related symptoms, the most frequently used acupoints were ST36 and SP6 to replenish *qi* and strengthen the spleen, LI4 to soothe static pain, LI11 to regulate *qi* and relieve pain, and GV4 to nourish vital energy. For symptoms related to mental and psychological disorders, the following acupoints were most frequently used: HT7 to calm the mind and nerves, ST36 with PC6 to soothe the liver and regulate *qi*, GV20 to awaken the brain and open the mind, and Ear trigel to regulate the *qi*. In general, selecting acupoints for COVID-19-related symptoms follows the treatment principle of syndrome differentiation.

In the fight against the pandemic, acupuncture therapy is widely used in the treatment of COVID-19. Acupuncture interventions are used to treat mild, moderate, and severe COVID-19, during convalescence, and for long COVID. Acupuncture combined with drug therapy has a synergistic effect and can promote recovery from COVID-19 and improve the quality of life of patients. Various acupuncture intervention methods are used, including manual acupuncture, filiform-fire needling, tube needle, thumb-tack needles, ear point pressure, intradermal needle, and acupoint injection, and there are little side effects. Different acupuncture methods can be selected for symptomatic treatment according to the condition



**Figure 5.** The role and possible mechanism of acupuncture in the treatment of COVID-19-related symptoms. 8-iso-PGF2α: 8-iso-prostaglandin F2α; ACTH: adrenocorticotropic hormone; Akt: protein kinase B; ATP: adenosine triphosphate; AngII: angiotensin II; AT1R: angiotensin II type 1 receptor; CRH: corticotropin-releasing hormones; ET-1: endothelin-1; ETAR: endothelin-1 type A receptor; JAK: the Janus kinase; PI3K: phosphatidylinositol 3-kinase; PVN: paraventricular nucleus; ROS: reactive oxygen species; SOD: superoxide dismutase; STAT: signal transducer and activator of transcription.

of the patient or the symptom characteristics of COVID-19 or long COVID. In addition, a characteristic of acupuncture therapy is that it affects multiple organs from one point. For example, ST36 is used to treat common digestive symptoms of COVID-19 and common nervous system symptoms and psychosocial disorders related to COVID-19, thus, playing a multi-target and multi-system regulatory role.

This study has several limitations. First, most of the included clinical studies are case reports or small-sample studies, and the quality of evidence is low, which affects the reliability of the results. Second, owing to the lack of case reports on acupuncture treatment for COVID-19 combined with the cardiovascular system and other basic diseases, the principles of acupoint selection for acupuncture treatment of cardiovascular system-related symptoms have not been summarized, and there is no agreement on the treatment course of acupuncture for COVID-19-related symptoms. Finally, basic research on acupuncture treatment for COVID-19-related symptoms is lacking. Therefore, we could only speculate on the possible mechanisms underlying the pathological process of COVID-19-related symptoms. As a next step, we will perform further relevant experimental research by collecting and analyzing evidence data from clinical practice to improve the level of evidence and the scientific accuracy of acupuncture interventions for COVID-19-related symptoms and long COVID.

In conclusion, acupuncture has certain advantages and characteristics in the treatment of COVID-19 and long COVID. The rate of acupuncture therapy for long COVID should be increased, and the core role of acupuncture in the treatment of long COVID should be investigated in rigorous studies so that it can be applied optimally for the treatment of COVID-19-related symptoms.

### Conflict of interest statement

The authors declare no conflict of interest.

### Funding

This study was financially supported by the National Natural Science Foundation of China (NSFC) (Nos. 82004467, 82030125 and 81573882); the National Key R&D Program of China (No. 2019YFC1712200-2019YFC1712204).

### Author contributions

The authors contributed in the following manner: Lifen Wang and Xiyou Hu contributed to the concept design, data collection, and paper writing; Xinru Yuan, Jinyu Lian, Xiaoyan Lyu contributed to the figures and graphic abstract edit; Lihong Huang, Dongsheng Ba contributed to the data collection and analysis; Ningcen Li, Yong Chen, Jingyu Zhang contributed to the language modification and text check; and Zelin Chen, Bo Chen, Yue Zhang and Lianqi Geng contributed to the concept design and paper review. Lifen Wang and Xiyou Hu contributed equally to this work. All authors have read and approved the final manuscript.

### Ethical approval of studies and informed consent

Not applicable.

### Acknowledgements

None.

### Data Availability

All data generated or analyzed during this study are included in this published article.

### References

- [1] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395(10223):507–513.
- [2] WHO. Coronavirus disease (COVID -19) weekly epidemiological update on COVID-19. 2022. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/>. Accessed December 18, 2022.
- [3] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497–506.
- [4] Chen R, Lan Z, Ye J, et al. Cytokine storm: the primary determinant for the pathophysiological evolution of COVID-19 deterioration. *Front Immunol* 2021;12:589095.
- [5] National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available from: <https://www.covid-19-treatment-guidelines.nih.gov>. Accessed January 26, 2023.
- [6] National Health Commission. National health commission diagnosis and treatment plan for novel coronavirus pneumonia (trial version10). Available from: [http://www.gov.cn/zhengce/zhengceku/2023-01/06\\_content\\_5735343.htm](http://www.gov.cn/zhengce/zhengceku/2023-01/06_content_5735343.htm). Accessed January 6, 2023.
- [7] Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in COVID-19. *BMJ* 2020;369:m1432.
- [8] Al-aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature* 2021;594(7862):259–264.
- [9] Spinner CD, Gottlieb RL, Criner GJ, et al; GS-US-540-5774 Investigators. Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. *JAMA* 2020;324(11):1048–1057.
- [10] World Health Organization. Coronavirus disease (COVID-19): post COVID-19 condition. Available from: [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covid-19\)-post-covid-19-covid-19-condition](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-covid-19-condition). Accessed December 16, 2021.
- [11] Proal AD, Vanelzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. *Front Microbiol* 2021;12:698169.
- [12] Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. *Nat Immunol* 2022;23(2):210–216.
- [13] Liu Q, Mak J, Su Q, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. *Gut* 2022;71(3):544–552.
- [14] Haffke M, Freltag H, Rudolf G, et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). *J Transl Med* 2022;20(1):138.
- [15] Shan W, Hillman T, Playford ED, et al. Managing the long term effects of covid-19:summary of NICE, SIGN, and RCGP rapid guideline. *BMJ* 2021;372:n136.
- [16] Davis HE, Mccorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023;21(3):133–146.
- [17] Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. *Infect Dis (Lond)* 2021;53(10):737–754.
- [18] Von TP, Oei SL, Ramsenthaler C. Acupuncture for breathlessness in advanced diseases:a systematic review and meta-analysis. *J Pain Symptom Manage* 2020;59(2):327–338.e3.

- [19] Xu S, Yu L, Luo X, et al. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. *BMJ* 2020;368:m697.
- [20] Li YY, Yin CY, Li XJ, et al. Electroacupuncture alleviates paclitaxel-induced peripheral neuropathic pain in rats via suppressing TLR4 signaling and TRPV1 upregulation in sensory neurons. *Int J Mol Sci* 2019;20(23):5917.
- [21] Feng D, Zhou H, Jin X, et al. Electroacupuncture pretreatment alleviates LPS-induced acute respiratory distress syndrome via regulating the PPAR Gamma/NF-Kappa B signaling pathway. *Evid Based Complement Alternat Med* 2020;2020:4594631.
- [22] Zhao X, Liu L, Wang Y, et al. Electroacupuncture enhances antioxidative signal pathway and attenuates neuropathic pain induced by chemotherapeutic paclitaxel. *Physiol Res* 2019;68(3):501–510.
- [23] Zhou F, Jiang H, Kong N, et al. Electroacupuncture attenuated anxiety and depression-like behavior via inhibition of hippocampal inflammatory response and metabolic disorders in TNBS-induced IBD rats. *Oxid Med Cell Longev* 2022;2022:8295580.
- [24] Lai CC, Ko WC, Lee PI, et al. Extra-respiratory manifestations of COVID-19. *Int J Antimicrob Agents* 2020;56(2):106024.
- [25] Rendeiro AF, Ravichandran H, Bram Y, et al. The spatial landscape of lung pathology during COVID-19 progression. *Nature* 2021;593(7860):564–569.
- [26] Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: a meta-analysis. *J Med Virol* 2020;92(10):1902–1914.
- [27] Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. *PLoS One* 2020;15(6):e0234765.
- [28] Koh J, Shah SU, Chua P, et al. Epidemiological and clinical characteristics of cases during the early phase of COVID-19 pandemic: a systematic review and meta-analysis. *Front Med (Lausanne)* 2020;7:295.
- [29] Rodriguez AJ, Cardona JA, Gutierrez E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. *Travel Med Infect Dis* 2020;34:101623.
- [30] Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol* 2020;92(6):577–583.
- [31] Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. *J Med Virol* 2020;92(6):612–617.
- [32] Cao Y, Liu X, Xiong L, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. *J Med Virol* 2020;92(9):1449–1459.
- [33] Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. *J Infect* 2020;80(6):656–665.
- [34] Park JH, Jang W, Kim SW, et al. The clinical manifestations and chest computed tomography findings of coronavirus disease 2019 (COVID-19) patients in China: a proportion meta-analysis. *Clin Exp Otorhinolaryngol* 2020;13(2):95–105.
- [35] Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis* 2020;94:91–95.
- [36] Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis executive summary. *Otolaryngol Head Neck Surg* 2015;152(2):197–206.
- [37] McCullough AR, Pollack AJ, Plejdrup HM, et al. Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations. *Med J Aust* 2017;207(2):65–69.
- [38] Elnaggar RK, Moawd SA, Ali SE, et al. Potential impacts of AcUTENS in the treatment of adolescents with moderate to severe bronchial asthma: a randomized clinical study. *Complement Ther Med* 2021;57:102673.
- [39] Wang J, Li J, Yu X, et al. Acupuncture therapy for functional effects and quality of life in COPD patients: a systematic review and meta-analysis. *Biomed Res Int* 2018;2018:3026726.
- [40] Xiong J, Qi W, Yang H, et al. Acupuncture treatment for cough-variant asthma: a meta-analysis. *Evid Based Complement Alternat Med* 2021;2021:6694936.
- [41] Wang H, Ying H, Wang S, et al. Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease. *Clin Respir J* 2015;9(3):330–341.
- [42] Yang CH, Tian JJ, Ko WS, et al. Oligo-fucoidan improved unbalance the Th1/Th2 and Treg/Th17 ratios in asthmatic patients: an ex vivo study. *Exp Ther Med* 2019;17(1):3–10.
- [43] Liang P, Peng S, Zhang M, et al. Huai Qi Huang corrects the balance of Th1/Th2 and Treg/Th17 in an ovalbumin-induced asthma mouse model. *Biosci Rep* 2017;37(6):BSR20171071.
- [44] Sun J, Liu T, Yan Y, et al. The role of Th1/Th2 cytokines played in regulation of specific CD4 (+) Th1 cell conversion and activation during inflammatory reaction of chronic obstructive pulmonary disease. *Scand J Immunol* 2018;88(1):e12674.
- [45] Zhao H, Dong F, Li Y, et al. Inhibiting ATG5 mediated autophagy to regulate endoplasmic reticulum stress and CD4(+) T lymphocyte differentiation: mechanisms of acupuncture's effects on asthma. *Biomed Pharmacother* 2021;142:112045.
- [46] Li D, Sun T, Chi L, et al. Acupoint catgut embedding improves the lipopolysaccharide-induced acute respiratory distress syndrome in rats. *Biomed Res Int* 2020;2020:2394734.
- [47] Zhang XF, Xiang SY, Geng WY, et al. Electro-acupuncture regulates the cholinergic anti-inflammatory pathway in a rat model of chronic obstructive pulmonary disease. *J Integr Med* 2018;16(6):418–426.
- [48] Hua JS, Li HJ, Chen F, et al. Effect of acupuncture preconditioning combined with PI3K blocker LY294002 on airway inflammation in asthmatic rats. *Zhen Ci Yan Jiu* 2022;47(9):778–784.
- [49] Geng WY, Liu ZB, Song NN, et al. Effects of electroacupuncture at Zusanli (ST36) on inflammatory cytokines in a rat model of smoke-induced chronic obstructive pulmonary disease. *J Integr Med* 2013;11(3):213–219.
- [50] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323(11):1061–1069.
- [51] Rokkas T. Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis. *Ann Gastroenterol* 2020;33(4):355–365.
- [52] Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020;5(7):667–678.
- [53] Cheung KS, Hung I, Chan P, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. *Gastroenterology* 2020;159(1):81–95.
- [54] Suresh VC, Mukherjee S, Harne PS, et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. *BMJ Open Gastroenterol* 2020;7(1):e000417.
- [55] Lyman GH, Greenlee H, Bohlke K, et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. *J Clin Oncol* 2018;36(25):2647–2655.
- [56] Shen J, Wenger N, Gaspy J, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: a randomized controlled trial. *JAMA* 2000;284(21):2755–2761.
- [57] Qi LY, Yang JW, Yan SY, et al. Acupuncture for the treatment of diarrhea-predominant irritable bowel syndrome: a pilot randomized clinical trial. *JAMA Netw Open* 2022;5(12):e2248817.
- [58] Lee B, Ko MM, Lee SH, et al. Acupuncture for the treatment of childhood anorexia: a systematic review and meta-analysis. *Complement Ther Med* 2022;71:102893.
- [59] Chen J, Tu Q, Miao S, et al. Transcutaneous electrical acupoint stimulation for preventing postoperative nausea and vomiting after general anesthesia: a meta-analysis of randomized controlled trials. *Int J Surg* 2020;73:57–64.
- [60] Ren X, Zhu Y, Gamallat Y, et al. E. coli O124 K72 alters the intestinal barrier and the tight junctions proteins of guinea pig intestine. *Biomed Pharmacother* 2017;94:468–473.
- [61] Vindigni SM, Zisman TL, Suskind DL, et al. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. *Therap Adv Gastroenterol* 2016;9(4):606–625.
- [62] Hou TS, Han XX, Yang Y, et al. Effect of electroacupuncture intervention on enteric microecology in ulcerative colitis rats. *Zhen Ci Yan Jiu* 2014;39(1):27–34.
- [63] Wang L, An J, Song S, et al. Electroacupuncture preserves intestinal barrier integrity through modulating the gut microbiota in DSS-induced chronic colitis. *Life Sci* 2020;261:118473.
- [64] Han YL, Peng XM, Zhang HX, et al. Electroacupuncture regulates TRPV1 through PAR2/PKC pathway to alleviate visceral hypersensitivity in FD rats. *Evid Based Complement Alternat Med* 2021;2021:1975228.
- [65] Yang J, Shang B, Shi H, et al. The role of toll-like receptor 4 and mast cell in the ameliorating effect of electroacupuncture

- on visceral hypersensitivity in rats. *Neurogastroenterol Motil* 2019;31(6):e13583.
- [66] Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J Exp Med* 2021;218(3):e20202135.
- [67] Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol* 2020;92(6):552–555.
- [68] Chiu CW, Lee TC, Hsu PC, et al. Efficacy and safety of acupuncture for dizziness and vertigo in emergency department: a pilot cohort study. *BMC Complement Altern Med* 2015;15:173.
- [69] Greenlee H, Dupont MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. *CA Cancer J Clin* 2017;67(3):194–232.
- [70] Wang T, Xu C, Pan K, et al. Acupuncture and moxibustion for chronic fatigue syndrome in traditional Chinese medicine: a systematic review and meta-analysis. *BMC Complement Altern Med* 2017;17(1):163.
- [71] Li X, Dai Q, Shi Z, et al. Clinical efficacy and safety of electroacupuncture in migraine treatment: a systematic review and network meta-analysis. *Am J Chin Med* 2019;47(8):1755–1780.
- [72] Swartjes M, Moraariu A, Niesters M, et al. Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain. *Anesthesiology* 2011;115(1):165–174.
- [73] Huang CP, Lin YW, Lee DY, et al. Electroacupuncture relieves CCI-induced neuropathic pain involving excitatory and inhibitory neurotransmitters. *Evid Based Complement Alternat Med* 2019;2019:6784735.
- [74] Qiao LN, Liu JL, Tan LH, et al. Effect of electroacupuncture on thermal pain threshold and expression of calcitonin-gene related peptide, substance P and  $\gamma$ -aminobutyric acid in the cervical dorsal root ganglion of rats with incisional neck pain. *Acupunct Med* 2017;35(4):276–283.
- [75] Brkic S, Tomic S, Maric D, et al. Lipid peroxidation is elevated in female patients with chronic fatigue syndrome. *Med Sci Monit* 2010;16(12):CR628–632.
- [76] Zhu Y, Wang J, Yao L, et al. Electroacupuncture at BL15 attenuates chronic fatigue syndrome by downregulating iNOS/NO signaling in C57BL/6 mice. *Anat Rec (Hoboken)* 2022; published online May 24. <http://doi:10.1002/ar.24953>.
- [77] Wasserman D, Iosue M, Wuestefeld A, et al. Adaptation of evidence-based suicide prevention strategies during and after the COVID-19 pandemic. *World Psychiatry* 2020;19(3):294–306.
- [78] Tan YQ, Wang Z, Yap QV, et al. Psychological health of surgeons in a time of COVID-19: a global survey. *Ann Surg* 2021;277(1):50–56.
- [79] Qaseem A, Barry MJ, Kansagara D; Clinical Guidelines Committee of the American College of Physicians. Nonpharmacologic versus pharmacologic treatment of adult patient with major depressive disorder: a clinical practice guideline from the American college of physicians. *Ann Intern Med* 2016;164(5):350–359.
- [80] Yin X, Li W, Liang T, et al. Effect of electroacupuncture on insomnia in patients with depression: a randomized clinical trial. *JAMA Netw Open* 2022;5(7):e2220563.
- [81] Li M, Niu J, Yan P, et al. The effectiveness and safety of acupuncture for depression: an overview of meta-analyses. *Complement Ther Med* 2020;50:102202.
- [82] Zhi CH, Ching LW, Hui JL, et al. A network meta-analysis on the effectiveness and safety of acupuncture in treating patients with major depressive disorder. *Sci Rep* 2021;11(1):10384.
- [83] Maes M, Carvalho AF. The compensatory immune-regulatory reflex system (CIRS) in depression and bipolar disorder. *Mol Neurobiol* 2018;55(12):8885–8903.
- [84] Kandola A, Ashdown G, Hendrikse J, et al. Physical activity and depression: towards understanding the antidepressant mechanisms of physical activity. *Neurosci Biobehav Rev* 2019;107:525–539.
- [85] Le JJ, Yi T, Qi L, et al. Electroacupuncture regulate hypothalamic-pituitary-adrenal axis and enhance hippocampal serotonin system in a rat model of depression. *Neurosci Lett* 2016;615:66–71.
- [86] Chen Y, Hao C, Chen W, et al. Anti-depressant effects of acupuncture: the insights from NLRP3 mediated pyroptosis and inflammation. *Neurosci Lett* 2022;785:136787.
- [87] Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. *J Clin Endocrinol Metab* 2001;86(8):3787–3794.
- [88] Zhou Y, Chi J, Lv W, et al. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). *Diabetes Metab Res Rev* 2021;37(2):e3377.
- [89] Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet* 2020;395(10239):1763–1770.
- [90] Li Y, Barajas H, Li B, et al. Comparative effectiveness of acupuncture and antiarrhythmic drugs for the prevention of cardiac arrhythmias: a systematic review and meta-analysis of randomized controlled trials. *Front Physiol* 2017;8:358.
- [91] Yang J, Chen J, Yang M, et al. Acupuncture for hypertension. *Cochrane Database Syst Rev* 2018;11(11):CD008821.
- [92] Zhao L, Li D, Zheng H, et al. Acupuncture as adjunctive therapy for chronic stable angina: a randomized clinical trial. *JAMA Intern Med* 2019;179(10):1388–1397.
- [93] Liu Y, Meng HY, Khurwolah MR, et al. Acupuncture therapy for the treatment of stable angina pectoris: an updated meta-analysis of randomized controlled trials. *Complement Ther Clin Pract* 2019;34:247–253.
- [94] Diabetes Branch of Chinese Medical Association. Chinese guidelines for the prevention and treatment of type 2 diabetes (2020 Edition). *Chin J Endocrine Metab* 2021;37(4):311–398.
- [95] Zhang T, Yang WX, Wang YL, et al. Electroacupuncture preconditioning attenuates acute myocardial ischemia injury through inhibiting NLRP3 inflammasome activation in mice. *Life Sci* 2020;248:117451.
- [96] Wang C, Liang X, Yu Y, et al. Electroacupuncture pretreatment alleviates myocardial injury through regulating mitochondrial function. *Eur J Med Res* 2020;25(1):29.
- [97] Li P, Tjen SC. Mechanism of the inhibitory effect of electroacupuncture on experimental arrhythmias. *J Acupunct Meridian Stud* 2013;6(2):69–81.
- [98] Cacciapuoti F. Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives. *J Am Soc Hypertens* 2011;5(6):449–455.
- [99] Huo ZJ, Li Q, Tian GH, et al. The ameliorating effects of long-term electroacupuncture on cardiovascular remodeling in spontaneously hypertensive rats. *BMC Complement Altern Med* 2014;14:118.
- [100] Lan D, Xu N, Sun J, et al. Electroacupuncture mitigates endothelial dysfunction via effects on the PI3K/Akt signalling pathway in high fat diet-induced insulin-resistant rats. *Acupunct Med* 2018;36(3):162–169.
- [101] Bhat AK, Krishna KV, Johnson JD. An integrative approach with Ayurveda and Traditional Chinese Acupuncture in post covid parosmia - A case study. *J Ayurveda Integr Med* 2023;14(1):100560.
- [102] Yin X, Cai SB, Chen LM, et al. 17 cases of severe COVID-19 treated with acupuncture and medicine. *Zhongguo Zhen Jiu* 2021;41(05):498–500.
- [103] Yin X, Cai SB, Tao LT, et al. Recovery of a patient with severe COVID-19 by acupuncture and Chinese herbal medicine adjunct to standard care. *J Integr Med* 2021;19(5):460–466.
- [104] Tao LT, Huang TL, Zheng DW, et al. Case of professor Xu ZOU's acupuncture technique for “benefiting kidney and strengthening anti-pathogenic qi” in promoting the absorption of COVID-19. *World J Acupunct Moxibustion* 2020;30(3):167–170.
- [105] Luo ZH, Wang KX, Zhang YL, et al. Clinical observation on filiform-fire needling of “Biaoben acupoint combination” for 33 cases of sequelae of coronavirus disease 2019 during recovery period. *Zhongguo Zhen Jiu* 2022;42(7):760–764.
- [106] Li ZJ, Cai QX, Yuan J, etc. Clinical study on Xueshuantong point injection for novel coronavirus pneumonia. *Shanghai J Acupunct Moxibust* 2021,40(10):1182–1184.
- [107] Wang H, Dai C, Xiao L, et al. Clinical efficacy and safety of intracutaneous acupuncture combined with western medicine in the treatment of 3 cases of severe COVID-19. *Chin J Hospital Infect* 2021;31(24):3699–3702.
- [108] Cheng SI. Medical acupuncture as a treatment for novel COVID-19-related respiratory distress: personal experience from a front-line anesthesiologist. *Med Acupunct* 2021;33(1):83–85.
- [109] Wang YZ, Li B, Wang LP, et al. Acupuncture as adjuvant therapy for 32 cases of coronavirus disease 2019. *Zhongguo Zhen Jiu* 2022;42(6):634–638.
- [110] Jania C. The treatment of long COVID with Chinese medicine: a case report. *J Chin Med* 2021;2021(127):17–22.
- [111] Gong YB, Shi XJ, Zhang Y, etc. Clinical application and practice of acupuncture therapy in novel coronavirus pneumonia. *Zhongguo Zhen Jiu* 2021;41(2):142–144.

- [112] Gong YB, Shi XJ, Zhang Y, et al. Practice and experience in treating novel coronavirus pneumonia with tube acupuncture in negative pressure ward. *Shanghai J Acupuncture Moxibustion* 2021;40(4):487–490.
- [113] Luo ZH, Wang KX, Zhang YL, et al. Thumb-tack needles based on “Biaoben acupoint compatibility” for sequela of COVID-19 during recovery period. *Zhongguo Zhen Jiu* 2022;42(3):281–286.
- [114] Luo YH, Luo YF, Hu SF. Observation on ear point pressing beans combined with Yijinjing to improve stress disorder in mild COVID-19 patients. *Pract Clin Med* 2021;22(1):57–59.
- [115] Yang C, Ma Y, Mei JH, et al. Observation of therapeutic effect on coronavirus disease 2019 with insomnia in treatment with baduanjin and auricular point sticking therapy. *Zhongguo Zhen Jiu* 2021;41(3):243–246.
- [116] Gong YB, Yang ZL, Liu Y, et al. Two cases of corona virus disease 2019 (COVID-19) treated with the combination of acupuncture and medication in bedridden patients. *World J Acupunct Moxibustion* 2020;30(3):171–174.
- [117] Trager RJ, Brewka EC, Kaiser CM, et al. Acupuncture in multidisciplinary treatment for post-COVID-19 syndrome. *Med. Acupunct* 2022;34(3):177–183.

---

**How to cite this article:** Wang LF, Hu XY, Geng LQ, Li NC, Chen Y, Zhang JY, Yuan XR, Huang LH, Ba DS, Lian JY, Lyu XY, Chen ZL, Zhang Y, Chen B. Multi-effective characteristics and advantages of acupuncture in COVID-19 treatment. *Acupunct Herb Med* 2023;3(2):83–95. doi: 10.1097/HM9.0000000000000062